Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 15, 2026, 9:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Omission of Radiation Clear all

Conditions: Small Cell Lung Cancer Extensive Stage, Brain Metastases, Solid Tumor, Adult, Thoracic Cancer, Sarcoma,Soft Tissue, HNPCC
Interventions: Cohort A: Extensive Stage Small Cell Lung Cancer (ES-SCLC) Thoracic Tumor PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy), Cohort B: Brain metastasis PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy), Cohort C: Sarcoma Pre-Operative PULSAR, Cohort D: Resectable Head & Neck Squamous Cell Carcinoma (HNSCC) PULSAR/SAbR; Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hematologic Neoplasms
Interventions: Omission of the drug mycophenolate mofetil; Other
Lead sponsor: Ronald Paquette; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer Radiation
Interventions: Prosigna; Device
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 50 Years to 75 Years · Female only
Enrollment: 671 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2030
U.S. locations: 6
States / cities: Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more

Conditions: Breast Neoplasms
Interventions: endocrine therapy alone without radiotherapy; Other
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 50 Years to 69 Years · Female only
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 13
States / cities: Stanford, California • New Haven, Connecticut • Maywood, Illinois + 10 more

Conditions: Ductal Carcinoma in Situ of the Breast
Interventions: Observation; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Breast Cancer Female
Interventions: Arm A: Radiotherapy Omission, Arm B: Standard Treatment; Radiation · Other
Lead sponsor: Breast Cancer Trials, Australia and New Zealand; Other
Eligibility: 50 Years and older · Female only
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2039
U.S. locations: 2
States / cities: San Francisco, California • Houston, Texas

Conditions: Breast Cancer
Interventions: Lumpectomy without sentinel node biopsy; Procedure
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer
Interventions: Adjuvant Radiotherapy; Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 60 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Rectal Cancer
Interventions: Ultrafractionated radiotherapy for rectal cancer; Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Metastatic Cancer
Interventions: conventional surgery, radiation therapy; Procedure · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HER2-positive Breast Cancer
Interventions: Omission of Radiation; Radiation
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 40 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Estrogen Receptor Negative, HER2 Positive Breast Carcinoma, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
Interventions: Undergo EBRT, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Partial Breast Irradiation; Radiation · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 30 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 8
States / cities: Gilbert, Arizona • Jacksonville, Florida • Honolulu, Hawaii + 5 more

Conditions: Squamous Cell Carcinoma, Human Papilloma Virus (HPV), Oropharyngeal Squamous Cell Carcinoma (OPSCC)
Interventions: Active Surveillance With ctHPVDNA (NavDx®); Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Breast Cancer
Interventions: Lumpectomy without sentinel node biopsy; Procedure
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 65 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)

Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil

The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer

The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)

Wide Excision Alone as Treatment for Ductal Carcinoma in Situ of The Breast

Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)

Safety and Efficacy of Sentinel Node Biopsy Omission for Breast Cancer Patients Who Plan to Have Adjuvant Chemotherapy

EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial

Ultra-fractionated Radiotherapy for Rectal Cancer

Radiation Therapy With or Without Surgery in Treating Patients Who Have Brain Metastases

Omission of Radiation in Patients With Her-2 Positive Breast Cancer

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)

Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Estrogen-Positive Breast Cancer Over Age 65